Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Owens-Illinois Inc (OI): Alexander Roepers’ Atlantic Investment Management Ups Activist Stake to 6.7%

Atlantic Investment Management has revealed upping its stake in Owens-Illinois Inc (NYSE:OI) to 11.0 million shares, which is significantly above the previous position of 9.4 million shares that the fund revealed in its latest 13F. Following the increase, Atlantic Investment Management, which is led by Alexander J. Roepers, owns an activist stake that amasses 6.7% of the company’s common stock.

Alexander Roepers

Another hedge fund that owns shares of Owens-Illinois Inc (NYSE:OI) is Robert Rodriguez and Steven Romick‘s First Pacific Advisors LLC, which last disclosed holding 6.2 million shares of the $4.6 billion company. Thomas Steyer‘s Farallon Capital upped its stake by 18% during the first quarter to 4.65 million, held as of the end of June.

Owens manufacturers glass containers for different food and beverage brands. The company produces glass packaging for food, cosmetics, pharmaceuticals, and beverages. Owens-Illinois Inc (NYSE:OI) reported a net income of $0.80 per share for the second quarter of the year, which is slightly below $0.81 for the same period of last year. The net sales of the company slightly grew to $1.80 billion from $1.78 billion.

Despite solid results, the stock price of Owens-Illinois Inc (NYSE:OI) declined by over 21% since the beginning of the year. In fact, the decline is one of the largest in the packaging & containers industry, which overall has returned around 2% year-to-date. However, the company trails a P/E of 24.00, which is above the industry average of 19.00. For the current year, analysts expect the company to post EPS of $2.72 per share, which is above $2.72 reported for the last year.  In addition, the revenue outlook for the current year stands at $7.0 billion, which is in line with the last year’s result.

Disclosure: none

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!